GlassScriptPhysician profile
Marc Gutin
NPI 1861423709
$39,187.49
in general payments reported to CMS, 2019-2025
57 companies · $3,196 in 2025
The $3,196 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,476 · 2020: $9,060 · 2021: $6,489 · 2022: $3,341 · 2023: $4,099 · 2024: $3,527 · 2025: $3,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Travel and Lodging: $376 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,413.05 |
| Travel and Lodging | $376.29 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,052.19 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $6,506.54 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $2,646.98 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $2,450.25 | 2019-2025 | Evenity, Prolia, Tepezza |
| Mannkind Corporation | $2,117.53 | 2019-2024 | Afrezza |
| Dexcom, INC. | $1,778.78 | 2019-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $1,554.53 | 2019-2025 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $1,157.26 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $970.94 | 2021-2025 | Minimed 780g, Minimed 770g |
| Sanofi-Aventis U.S. LLC | $831.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $725.88 | 2019-2024 | Farxiga |
| Antares Pharma, INC. | $445.15 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Esperion Therapeutics, INC. | $416.92 | 2021-2025 | Nexletol |
| Abbvie INC. | $412.98 | 2019-2025 | |
| Horizon Therapeutics Plc | $379.06 | 2021-2023 | Tepezza |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Gutin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.